APVO451 / Aptevo Therap - LARVOL DELTA

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development (The Globe and Mail) - "Aptevo expects to enter Investigational New Drug ('IND') enabling studies for the lead candidate, APVO451, in 1H2027....Aptevo expects to present additional details on these ongoing development activities at an upcoming international scientific conference."

IND • Solid Tumor

...APVO451 as an emerging pipeline value driver, with development candidate selection targeted by year-end 2026 and IND-enabling studies planned for the first quarter of 2027. (Yahoo Finance)

Pipeline update • Preclinical • Solid Tumor

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors (StockTitan.net) - "The grant funds preclinical and development activities toward development candidate selection by year-end 2026 and IND-enabling studies in Q1 2027."

Financing • IND • Solid Tumor

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors (ACCESS Newswire) - "Key Findings from the Presentation: Local Activation in the Tumor: APVO451 triggered T-cell and APC activation only when bound to the target nectin-4, suggesting the potential for strong immune activity without systemic over-activation resulting in a potentially favorable safety profile; Dual Immune Re-Activation: The molecule stimulated the effector functions of T-cells and restored APC function - two arms of the immune system that cause treatments to often fail in solid tumors due to the tumors' ability to suppress the immune system; Activity Under Suppressive Conditions: In cultured tumor models designed to mimic tumor suppression, APVO451 eliminated nectin-4-positive tumor cells more effectively than a standard CD3 T-cell engager potentially demonstrating the ability of APVO451 to overcome a suppressive tumor microenvironment."

Preclinical • Breast Cancer • Pancreatic Cancer • Urothelial Cancer

A breakthrough in fighting solid tumors with a novel trispecific targeting Nectin-4, CD3 and CD40 to overcome the immunosuppressive tumor microenvironment (SITC 2025) - "The CD40-directed arm of APVO451 led to the induction of IL-12 secretion and upregulation of CD80/CD86, which may play an important role in overcoming the suppression of MDSC in the TME. This trispecific antibody is a promising anti-cancer therapeutic for the treatment of various solid tumors with suppressive TME via costimulation of APC while simultaneously providing signal 1 to tumor-infiltrating T cells."

Biomarker • Trispecific • Tumor microenvironment • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD40 • CD80 • CD86 • IL12A • NECTIN4

Society of Immunotherapy in Cancer (SITC) 2025 - 40th Anniversary Annual Meeting (ACCESS Newswire) - "Aptevo's R&D Team will present a poster highlighting a novel trispecific targeting Nectin-4, CD3 and CD40 to overcome the immunosuppressive the tumor microenvironment."

Preclinical • Oncology

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules (ACCESS Newswire) - "Aptevo Therapeutics Inc...announced expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451 for prostate cancer and multiple, additional solid tumor types with significant unmet needs."

New molecule • Prostate Cancer • Solid Tumor